Contact | Beizray

Who to contact

Service/Support	Hours of operation	Phone	E-mail
Medical Affairs / Adverse Event Reporting	Hours of Operation: 9:00 AM – 5:00 PM EST Monday-Friday	P: 877-993-8779, F: +1-609-559-0699	medicalaffairs@zydususa.com
Customer Service	Hours of Operation: 8:30 AM – 5:00 PM EST Monday-Friday	P: 877-993-8779, F: +1-877-993-9055	customerservice@zydususa.com

Medical Affairs / Adverse Event Reporting

Hours of Operation:
9:00 AM – 5:00 PM EST Monday-Friday

P: 877-993-8779,
F: +1-609-559-0699

medicalaffairs@zydususa.com

Customer Service

Hours of Operation:
8:30 AM – 5:00 PM EST Monday-Friday

P: 877-993-8779,
F: +1-877-993-9055

customerservice@zydususa.com

Your regional Beizray representative

State representative
email address

Your regional Beizray representative

For support with ordering please contact your dedicated representative

BEIZRAY 80 mg kit
NDC 70710-2091-3

Strength	NDC	Cardinal Specialty	Cencora (ASD)	McKesson Plasma & Biologics	McKesson Specialty	Oncology Supply
		10304417	6055446	3063427	5021363	10304486

BEIZRAY 160 mg kit
NDC 70710-2093-4

Strength	NDC	Cardinal Specialty	Cencora (ASD)	McKesson Plasma & Biologics	McKesson Specialty	Oncology Supply
		10304461	6055453	3063435	5021364	10304439

Strength	NDC	Cardinal Specialty	Cencora (ASD)	McKesson Plasma & Biologics	McKesson Specialty	Oncology Supply
BEIZRAY 80 mg kit	70710-2091-3	6055446	10304417	3063427	5021363	10304486
BEIZRAY 160 mg kit	70710-2093-4	6055453	10304461	3063435	5021364	10304439

WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION

See full prescribing information for complete boxed warning.

Treatment-related mortality increases with abnormal liver function, at higher doses, and in patients with NSCLC and prior platinum-based therapy receiving BEIZRAY at 100 mg/m².
Avoid use of BEIZRAY if bilirubin > ULN, or if AST and/or ALT >1.5 × ULN concomitant with alkaline phosphatase >2.5 × ULN. LFT elevations increase risk of severe or life-threatening complications. Obtain LFTs before each treatment cycle.
Do not administer BEIZRAY to patients with neutrophil counts <1500 cells/mm³. Obtain frequent blood counts to monitor for neutropenia.
Severe hypersensitivity, including fatal anaphylaxis, has been reported in patients who received dexamethasone premedication. Severe reactions require immediate discontinuation of BEIZRAY and administration of appropriate therapy.
Contraindicated if history of severe hypersensitivity reactions to docetaxel.
Severe fluid retention may occur despite dexamethasone.